Quantitative detection of rivaroxaban based on far-IR absorbance spectroscopy and Raman spectroscopy

被引：0
|
作者：
Lv J. [1 ]
机构：
[1] Beijing ZKYH Technology Co., Ltd, Beijing
来源：
Hongwai yu Jiguang Gongcheng/Infrared and Laser Engineering | 2021年 / 50卷 / 02期
关键词：
Far-IR absorbance spectroscopy; Quantitative detection; Raman spectroscopy; Rivaroxaban;
D O I：
10.3788/IRLA20210038
中图分类号：
学科分类号：
摘要：
Rivaroxaban is a new type of oral anticoagulant, which has the advantages of definite curative effect, good safety and convenient use, so it is often used in the prevention and treatment of venous thromboembolic diseases and stroke prevention of non valvular atrial fibrillation. Due to the concentration of rivaroxaban in patients, it will affect the inhibition of coagulation factor Xa, which leads to individual differences in the clinical response of patients and affects the final treatment effect. In order to use rivaroxaban more reasonably, it is necessary to monitor the concentration of rivaroxaban in human blood or urine. For the clinical needs, based on the advantages of far-infrared fingerprint spectrum and Raman characteristic spectrum in effective identification and quantitative analysis of substances, Fourier transform infrared spectrometer and laser confocal Raman spectroscopy system were used to identify and quantitatively detect rivaroxaban in liquid state. In this paper, the change of far-infrared absorption spectrum of rivaroxaban with its concentration was detected by Fourier transform infrared spectrometer, and then the change of Raman spectrum of rivaroxaban with its concentration was detected by laser confocal Raman spectroscopy system. Finally, the accuracy of far-infrared spectroscopy method and Raman method was compared. After comparison, it is proved that the accuracy of far-infrared detection is 2 times higher than that of Raman spectrum detection. These results are of great significance for the use of rivaroxaban in clinical medicine. Copyright ©2021 Infrared and Laser Engineering. All rights reserved.
引用
收藏
相关论文
共 17 条
  • [1] Kubitza D, Becka M, Voith B, Et al., Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor, Clinical Pharmacology & Therapeutics, 78, 4, pp. 412-421, (2005)
  • [2] Kirchhof P, Benussi S, Kotecha D, Et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, European Heart Journal, 37, 38, pp. 2893-2962, (2016)
  • [3] Maqsood M, Imran Hasan Khan M, Yameen M, Et al., Use of oral rivaroxaban in cerebral venous thrombosis, Journal of Drug Assessment, 10, 1, pp. 1-6, (2021)
  • [4] Weinz C, Schwarz T, Kubitza D, Et al., Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans, Drug Metabolism and Disposition, 37, 5, pp. 1056-1064, (2009)
  • [5] Harenberg J, Du S, Wehling M, Et al., Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study, Clinical Chemistry and Laboratory Medicine (CCLM), 54, 2, pp. 275-283, (2016)
  • [6] Mueck W, Lensing A W A, Agnelli G, Et al., Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for Stroke prevention, Clinical Pharmacokinetics, 50, 10, pp. 675-686, (2011)
  • [7] Shadvar K, Sadaghi P, Hamishekar H, Et al., Efficacy of prothrombin complex concentrate for reversal of major bleeding due to rivaroxaban: A pilot randomized controlled trial [J], Journal of Clinical Anesthesia, 68, (2021)
  • [8] Mueck W, Stampfuss J, Kubitza D, Et al., Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban, Clinical Pharmacokinetics, 53, 1, pp. 1-16, (2014)
  • [9] Plusquellic D F, Siegrist K, Heilweil E J, Et al., Applications of terahertz spectroscopy in biosystems, Chem Phys Chem, 8, 17, pp. 2412-2431, (2007)
  • [10] Cheng C, Zhu Z, Li S, Et al., Broadband terahertz recognizing conformational characteristics of a significant neurotransmitter γ-aminobutyric acid, RSC Advances, 9, pp. 20240-20247, (2019)
12